- Guidance for Endoscopic Procedures in Patients Taking Novel Oral Anticoagulants
-
Kim KO
- KMID: 2383557
- Korean J Helicobacter Up Gastrointest Res.
- 2016 Dec;16(4):185-188.
- doi: 10.7704/kjhugr.2016.16.4.185
Anticoagulant agents are used to reduce the risk of thromboembolic complications in patients with atrial fibrillation or deep vein thrombosis. Several new generation of oral anticoagulants have been approved. These... -
- CITED
-
- Close
- SHARE
-
- Close
- Series with complete resolution of left atrial appendage thrombi with apixaban in elderly patients
-
Lee SH, Han S
- KMID: 2373816
- Korean J Intern Med.
- 2016 Mar;31(2):396-398.
- doi: 10.3904/kjim.2015.131
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients
-
Joung B
- KMID: 2396475
- Korean Circ J.
- 2017 Nov;47(6):833-841.
- doi: 10.4070/kcj.2017.0158
Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation... -
- CITED
-
- Close
- SHARE
-
- Close
- Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban
-
Yang H, Kim SR, Song MJ
- KMID: 2373155
- Clin Mol Hepatol.
- 2016 Dec;22(4):499-502.
- doi: 10.3350/cmh.2016.0016
Cirrhosis can occur with the development of portal vein thrombosis (PVT). PVT may aggravate portal hypertension, and it can lead to hepatic decompensation. The international guideline recommends for anticoagulation treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
-
Lee JH, Oh YM, Lee SD, Lee JS
- KMID: 2456269
- J Korean Med Sci.
- 2019 Jun;34(21):e160.
- doi: 10.3346/jkms.2019.34.e160
BACKGROUND: Low-molecular-weight heparin (LMWH) is the standard treatment for venous thromboembolism (VTE) in patients with active cancer. However, use of factor Xa inhibitors, such as rivaroxaban, is increasing on the... -
- CITED
-
- Close
- SHARE
-
- Close
